UCB (OTCPK:UCBJ.Y) - Aktienkurs, Nachrichten und Analyse

Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

UCBJ.Y Aktienübersicht

UCB SA, ein biopharmazeutisches Unternehmen, entwickelt Produkte und Lösungen für Menschen mit neurologischen und immunologischen Erkrankungen weltweit.

Über das Unternehmen

UCBJ.Y fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	4/6
Past Performance	1/6
Financial Health	4/6
Dividends	4/6

Belohnungen

47.4% unter unserer Schätzung des beizulegenden Zeitwerts gehandelt

Prognostiziertes Gewinnwachstum 25.22% pro Jahr

Risikoanalyse

Bei unseren Risikoprüfungen wurden keine Risiken für UCBJ.Y festgestellt.

UCB SA Wettbewerber

Royalty Pharma

NasdaqGS:RPRX

US$15.9b

Zoetis

NYSE:ZTS

US$77.6b

Organon

NYSE:OGN

US$5.4b

Jazz Pharmaceuticals

NasdaqGS:JAZZ

US$6.7b

Preisentwicklung & Leistung

Summary of all time highs, changes and price drops for UCB
Historical stock prices
Current Share Price	€69.56
52 Week High	€70.13
52 Week Low	€34.85
Beta	0.38
1 Month Change	4.64%
3 Month Change	33.13%
1 Year Change	56.21%
3 Year Change	46.97%
5 Year Change	82.64%
Change since IPO	312.82%

Aktuelle Nachrichten und Updates

Recent updates

Aktionärsrenditen

	UCBJ.Y	US Pharmaceuticals	US Markt
7D	2.9%	0.1%	-0.2%
1Y	56.2%	18.6%	25.6%

Rendite im Vergleich zur Industrie: UCBJ.Y übertraf die Branche US Pharmaceuticals , die im vergangenen Jahr eine Rendite von 9.5 erzielte.

Rendite vs. Markt: UCBJ.Y übertraf den Markt US, der im vergangenen Jahr eine Rendite von 24.9 erzielte.

Preisvolatilität

Is UCBJ.Y's price volatile compared to industry and market?
UCBJ.Y volatility
UCBJ.Y Average Weekly Movement	3.6%
Pharmaceuticals Industry Average Movement	9.7%
Market Average Movement	5.9%
10% most volatile stocks in US Market	16.0%
10% least volatile stocks in US Market	2.8%

Stabiler Aktienkurs: UCBJ.YDer Aktienkurs des Unternehmens war in den letzten 3 Monaten unbeständig.

Volatilität im Zeitverlauf: UCBJ.YDie wöchentliche Volatilität (4%) ist im vergangenen Jahr stabil geblieben.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
1925	8,767	Jean-Christophe Tellier	www.ucb.com

UCB SA, ein biopharmazeutisches Unternehmen, entwickelt Produkte und Lösungen für Menschen mit neurologischen und immunologischen Erkrankungen weltweit. Zu den wichtigsten Produkten des Unternehmens gehören Cimzia für entzündliche TNF-vermittelte Erkrankungen sowie ankylosierende Spondylitis, axiale Spondyloarthritis, Morbus Crohn, nicht-radiographische axiale Spondyloarthritis, Plaque-Psoriasis, Psoriasis-Arthritis und rheumatoide Arthritis; Vimpat, Keppra und Briviact zur Behandlung von Epilepsie; Neupro zur Behandlung der Parkinson-Krankheit und des Syndroms der unruhigen Beine; Nayzilam, ein Nasenspray zur Behandlung von epileptischen Anfallskonzentrationen; sowie Zyrtec und Xyzal zur Behandlung von Allergien. Außerdem bietet es Evenity zur Behandlung von Osteoporose bei Frauen nach der Menopause, Bimzelx zur Behandlung von Plaque-Psoriasis, Psoriasis-Arthritis und axialer Spondyloarthritis sowie Fintepla zur Behandlung des Dravet-Syndroms an.

UCB SA's Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von UCB im Vergleich zum Marktanteil des Unternehmens?
UCBJ.Y grundlegende Statistiken
Marktanteil	US$26.45b
Gewinn(TTM)	US$372.14m
Umsatz(TTM)	US$5.62b

71.1x

Kurs-Gewinn-Verhältnis

4.7x

Kurs-Umsatz-Verhältnis

Ist UCBJ.Y zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
UCBJ.Y Gewinn- und Verlustrechnung (TTM)
Einnahmen	€5.18b
Kosten der Einnahmen	€1.71b
Bruttogewinn	€3.48b
Sonstige Ausgaben	€3.13b
Umsatz	€343.00m

Zuletzt gemeldete Gewinne

Dec 31, 2023

Datum des nächsten Gewinnberichts

Jul 25, 2024

Gewinn per Aktie (EPS)	1.81
Bruttomarge	67.06%
Nettogewinnspanne	6.62%
Schulden/Eigenkapital-Verhältnis	32.1%

Wie hat sich UCBJ.Y auf lange Sicht entwickelt?

Historische Performance und Vergleiche

Dividenden

1.1%

Aktuelle Dividendenrendite

75%

Ausschüttungsquote

UCBJ.Y Aktienübersicht

Belohnungen

Risikoanalyse

UCB SA Wettbewerber

NasdaqGS:RPRX

US$15.9b

NYSE:ZTS

US$77.6b

NYSE:OGN

US$5.4b

NasdaqGS:JAZZ

US$6.7b

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

UCB SA, Annual General Meeting, Apr 24, 2025

UCB Announces FDA Accepts Supplemental Biologics License Applications for Bimzelx

UCB Announces 48-Week Phase 3 Analyses of Pooled Phase 3 Data from the BE HEARD I and BE HEARD II Studies

UCB Presents New Data About the Real-World Experience of FINTEPLA® (Fenfluramine) and Rare Epilepsy Syndromes At 2023 American Epilepsy Society (AES) Annual Meeting

UCB SA Announces U.S. Availability of BIMZELX for the Treatment of Adults with Moderate-To-Severe Plaque Psoriasis

UCB to Present Post Hoc Analysis of the EXXELERATE Trial Evaluating the Efficacy of CIMZIA®? (Certolizumab Pegol) and Adalimumab in Patients with Rheumatoid Arthritis and High Rheumatoid Factor

Recent updates

UCB SA, Annual General Meeting, Apr 24, 2025

UCB Announces FDA Accepts Supplemental Biologics License Applications for Bimzelx

UCB Announces 48-Week Phase 3 Analyses of Pooled Phase 3 Data from the BE HEARD I and BE HEARD II Studies

UCB Presents New Data About the Real-World Experience of FINTEPLA® (Fenfluramine) and Rare Epilepsy Syndromes At 2023 American Epilepsy Society (AES) Annual Meeting

UCB SA Announces U.S. Availability of BIMZELX for the Treatment of Adults with Moderate-To-Severe Plaque Psoriasis

UCB to Present Post Hoc Analysis of the EXXELERATE Trial Evaluating the Efficacy of CIMZIA®? (Certolizumab Pegol) and Adalimumab in Patients with Rheumatoid Arthritis and High Rheumatoid Factor

UCB Presents Latest Data from Generalized Myasthenia Gravis Portfolio

UCB SA Announces Publication of NAYZILAM® (midazolam) Results in 'Epilepsy & Behavior' Examining the Impact of Dose on Return to Full Baseline Function (RTFBF) for People with Seizure Clusters

UCB Announces U.S. FDA Approves BIMZELX (Bimekizumab-Bkzx) for the Treatment of Adults with Moderate-To-Severe Plaque Psoriasis

UCB Announces U.S. FDA approval of ZILBRYSQ® (zilucoplan) for the Treatment of Adults with Generalized Myasthenia Gravis

UCB Reinforces Commitment to Advancing Care in Hidradenitis Suppurativa with Six Abstracts at SHSA 2023

UCB Announces Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis Suppurativa

UCB SA to Report Fiscal Year 2023 Results on Feb 21, 2024

Ucb Announces That Rystiggo Is Commercially Available for the Treatment of Adult Patients in the U.S. with Generalized Myasthenia Gravis (Gmg) Who Are Anti-Acetylcholine Receptor (Achr) or Anti-Muscle-Specific Tyrosine Kinase (Musk) Antibody Positive

UCB Announces Resignation of Head of Neurology Solutions Charl Van Zyl

UCB Announces Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial Spondyloarthritis

UCB SA to Report Fiscal Year 2022 Results on Feb 22, 2023

UCB Announces Rozanolixizumab BLA for the Treatment of Generalized Myasthenia Gravis Filed with U.S. FDA and Designated for Priority Review

UCB Announces Positive Phase 3 Studies for Bimekizumab in Hidradenitis Suppurativa

UCB SA to Present Data At the American Epilepsy Society 76Th Annual Meeting 2022 Supporting A Decades-Long Commitment to Transforming Epilepsy Care

UCB Announces the Publication of Long-Term Open-Label Extension (OLE) Study Results of FINTEPLA® (Fenfluramine) CIV in Epilepsia

UCB Announces U.S. FDA Acceptance of New Drug Application and EMA MAA Validation for Zilucoplan for the Treatment of Generalized Myasthenia Gravis in Adult Patients

UCB Announces the First Presentation of Long-Term, 52-Week Data from Three Phase 3 Studies Evaluating the Efficacy and Safety of Bimekizumab in Adults with Active Psoriatic Arthritis

UCB Announces New Three-Year Results from the BE BRIGHT Open-Label Extension Study

UCB, Announces New 24-Week Data from Two Phase 3 Studies, Be Mobile 1 and Be Mobile 2

UCB SA Announces First Detailed Data from Two Phase 3 Bimekizumab Studies in Psoriatic Arthritis to Be Presented At EULAR 2022

UCB SA, Annual General Meeting, Apr 27, 2023

UCB Presents Efficacy and Safety Results for Zilucoplan and Rozanolixizumab in Generalized Myasthenia Gravis

UCB Announces Jama Neurology Publishes Phase 3 Study Results on the Efficacy and Safety of Fintepla® (Fenfluramine) Oral Solution in Lennox-Gastaut Syndrome

UCB SA Announces Oral Solution Civ Approves for Treatment of Seizures Associated with Lennox-Gastaut Syndrome

UCB SA, Annual General Meeting, Apr 28, 2022

UCB Announces Positive Data in Myasthenia Gravis with Zilucoplan Phase 3 Study Results

UCB Announces Positive Top-Line Results for bimekizumab in Second Phase 3 Psoriatic Arthritis Study

UCB SA Announces Positive Top-Line Interim Analysis Results Showing That the Phase 3 Be Mobile 1 Study Met the Primary and All Ranked Secondary Endpoints

UCB SA Announces Positive Top-Line Interim Analysis Results from the Phase 3 Be Mobile 2 Study

UCB Announces Positive Phase 3 Results for Rozanolixizumab in Generalized Myasthenia Gravis

UCB Announces New Data from Rheumatology Portfolio Demonstrates Real World Value for Patients with axSpA, PsA, and Women of Childbearing Age

Insilico's Chemistry42 AI system integrated into UCB's drug discovery programs

UCB Announces Changes on Board of Directors

UCB SA to Report First Half, 2021 Results on Jul 29, 2021

doc.ai and UCB Teams Up to Develop Breakthrough Artificial Intelligence Models to Advance Care

UCB and Stanford Medicine Establish Multi-Year Collaboration

UCB Announces U.S. Food and Drug Administration Approval of VIMPAT

UCB SA (ENXTBR:UCB) agreed to acquire Handl Therapeutics from Gemma Frisius Fonds NV.

UCB Announces New Data on Its TNF Inhibitor

Bimekizumab Phase 3 Data Shows Superior Skin Clearance over Humira® in Moderate-To-Severe Psoriasis Patients

UCB Announces That the FDA and EMA Have Accepted the Biologics License Application (BLA) and Marketing Authorization Application (MAA), Respectively, for Bimekizumab for the Treatment of Adults with Moderate to Severe Plaque Psoriasis

UCB SA to Report Fiscal Year 2020 Results on Feb 25, 2021

UCB SA (ENXTBR:UCB) completed the acquisition of Ra Pharmaceuticals, Inc. (NasdaqGM:RARX) from Douglas A. Treco, New Enterprise Associates 13, L.P. managed by New Enterprise Associates and RA Capital Healthcare Fund, L.P managed by Ra Capital Management, LLC and others.

Aktionärsrenditen

Preisvolatilität

Über das Unternehmen

UCB SA's Grundlagenzusammenfassung

71.1x

4.7x

Erträge &amp; Einnahmen

Dividenden

1.1%

75%

Erträge & Einnahmen